Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease.

ABSTRACT:

SUBMITTER: Sun Q 

PROVIDER: S-EPMC8164054 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature